Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In the double-blind Phase III RECORD2 trial in 2,509 patients, rivaroxaban reduced
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury